[go: up one dir, main page]

MX2022015042A - Composiciones de trem y métodos relacionados con las mismas. - Google Patents

Composiciones de trem y métodos relacionados con las mismas.

Info

Publication number
MX2022015042A
MX2022015042A MX2022015042A MX2022015042A MX2022015042A MX 2022015042 A MX2022015042 A MX 2022015042A MX 2022015042 A MX2022015042 A MX 2022015042A MX 2022015042 A MX2022015042 A MX 2022015042A MX 2022015042 A MX2022015042 A MX 2022015042A
Authority
MX
Mexico
Prior art keywords
trem
compositions
methods relating
methods
trna
Prior art date
Application number
MX2022015042A
Other languages
English (en)
Inventor
Neil Kubica
Theonie Anastassiadis
Qingyi Li
David Charles Donnell Butler
Original Assignee
Flagship Pioneering Innovations Vi Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flagship Pioneering Innovations Vi Llc filed Critical Flagship Pioneering Innovations Vi Llc
Publication of MX2022015042A publication Critical patent/MX2022015042A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Detergent Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Immunology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)

Abstract

La divulgación se refiere en general a métodos para modular un parámetro de producción de un ARN correspondiente a, o un polipéptido codificado por, una secuencia de ácido nucleico que comprende un ORF endógeno que tiene un codón de terminación prematura, que comprende administrar una molécula efectora basada en ARNt que tiene una modificación de origen no natural.
MX2022015042A 2020-05-29 2021-05-28 Composiciones de trem y métodos relacionados con las mismas. MX2022015042A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063031941P 2020-05-29 2020-05-29
PCT/US2021/034999 WO2021243290A1 (en) 2020-05-29 2021-05-28 Trem compositions and methods relating thereto

Publications (1)

Publication Number Publication Date
MX2022015042A true MX2022015042A (es) 2023-03-09

Family

ID=76797080

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015042A MX2022015042A (es) 2020-05-29 2021-05-28 Composiciones de trem y métodos relacionados con las mismas.

Country Status (10)

Country Link
US (1) US20230203510A1 (es)
EP (1) EP4158031A1 (es)
JP (1) JP2023527413A (es)
KR (1) KR20230029685A (es)
CN (1) CN116018405A (es)
AU (1) AU2021278984A1 (es)
CA (1) CA3180101A1 (es)
IL (1) IL298539A (es)
MX (1) MX2022015042A (es)
WO (1) WO2021243290A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023009547A1 (en) * 2021-07-26 2023-02-02 Flagship Pioneering Innovations Vi, Llc Trem compositions and uses thereof
IL311867A (en) * 2021-10-13 2024-06-01 Flagship Pioneering Innovations Vi Llc Trem compositions and methods of use
CN117138048B (zh) * 2023-10-30 2024-02-02 中山大学中山眼科中心 Dock6在制备防治眼部新生血管性疾病药物中的应用

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US99823A (en) 1870-02-15 Improved indigo soap
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5801030A (en) 1995-09-01 1998-09-01 Genvec, Inc. Methods and vectors for site-specific recombination
WO1998051278A2 (en) 1997-05-14 1998-11-19 Inex Pharmaceuticals Corporation High efficiency encapsulation of charged therapeutic agents in lipid vesicles
US6693086B1 (en) 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
WO2002087541A1 (en) 2001-04-30 2002-11-07 Protiva Biotherapeutics Inc. Lipid-based formulations for gene transfer
EP1664316B1 (en) 2003-09-15 2012-08-29 Protiva Biotherapeutics Inc. Polyethyleneglycol-modified lipid compounds and uses thereof
JP4380411B2 (ja) 2004-04-30 2009-12-09 澁谷工業株式会社 滅菌方法
EP2992902A1 (en) 2004-12-27 2016-03-09 Silence Therapeutics GmbH Lipid complexes coated with peg and their uses
US7404969B2 (en) 2005-02-14 2008-07-29 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
US7451428B2 (en) 2005-02-24 2008-11-11 Texas Instruments Incorporated Merging sub-resolution assist features of a photolithographic mask through the use of a merge bar
GB0600948D0 (en) * 2006-01-18 2006-02-22 Univ Dundee Prevention/Treatment Of Ichthyosis Vulgaris, Atopy And Other Disorders
US20080042973A1 (en) 2006-07-10 2008-02-21 Memsic, Inc. System for sensing yaw rate using a magnetic field sensor and portable electronic devices using the same
CA3044134A1 (en) 2008-01-02 2009-07-09 Arbutus Biopharma Corporation Improved compositions and methods for the delivery of nucleic acids
PL2279254T3 (pl) 2008-04-15 2017-11-30 Protiva Biotherapeutics Inc. Nowe preparaty lipidowe do dostarczania kwasów nukleinowych
WO2009132131A1 (en) 2008-04-22 2009-10-29 Alnylam Pharmaceuticals, Inc. Amino lipid based improved lipid formulation
CA2984026C (en) 2008-10-09 2020-02-11 Arbutus Biopharma Corporation Improved amino lipids and methods for the delivery of nucleic acids
MX2011004268A (es) 2008-10-20 2011-06-01 Alnylam Pharmaceuticals Inc Composiciones y metodos para inhibir la expresion de transtiretina.
US8969353B2 (en) 2008-11-07 2015-03-03 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
WO2010054384A1 (en) 2008-11-10 2010-05-14 Alnylam Pharmaceuticals, Inc. Lipids and compositions for the delivery of therapeutics
JP5774486B2 (ja) 2008-11-10 2015-09-09 テクミラ ファーマシューティカルズ コーポレイションＴｅｋｍｉｒａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏｒｐｏｒａｔｉｏｎ 治療薬を送達するための新規な脂質及び組成物
CN102625696B (zh) 2009-06-10 2015-06-03 阿尔尼拉姆医药品有限公司 改进的脂质制剂
WO2011000106A1 (en) 2009-07-01 2011-01-06 Protiva Biotherapeutics, Inc. Improved cationic lipids and methods for the delivery of therapeutic agents
US8283333B2 (en) 2009-07-01 2012-10-09 Protiva Biotherapeutics, Inc. Lipid formulations for nucleic acid delivery
US9181295B2 (en) 2009-08-20 2015-11-10 Sirna Therapeutics, Inc. Cationic lipids with various head groups for oligonucleotide delivery
US20130022649A1 (en) 2009-12-01 2013-01-24 Protiva Biotherapeutics, Inc. Snalp formulations containing antioxidants
AU2010328336B2 (en) 2009-12-07 2017-03-02 Arbutus Biopharma Corporation Compositions for nucleic acid delivery
WO2011090965A1 (en) 2010-01-22 2011-07-28 Merck Sharp & Dohme Corp. Novel cationic lipids for oligonucleotide delivery
WO2011097480A1 (en) 2010-02-05 2011-08-11 University Of Louisville Research Foundation, Inc. Exosomal compositions and methods for the treatment of disease
JP4782232B1 (ja) 2010-04-09 2011-09-28 シャープ株式会社 光源モジュール、及びそれを備えた電子機器
US10077232B2 (en) 2010-05-12 2018-09-18 Arbutus Biopharma Corporation Cyclic cationic lipids and methods of use
CA2799091A1 (en) 2010-05-12 2011-11-17 Protiva Biotherapeutics, Inc. Cationic lipids and methods of use thereof
EP4481047A2 (en) 2010-06-03 2024-12-25 Alnylam Pharmaceuticals, Inc. Biodegradable lipids for the delivery of active agents
JP5957646B2 (ja) 2010-06-04 2016-07-27 サーナ・セラピューティクス・インコーポレイテッドＳｉｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． オリゴヌクレオチド送達のための新規な低分子量カチオン性脂質
US9006417B2 (en) 2010-06-30 2015-04-14 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
WO2012006551A2 (en) * 2010-07-08 2012-01-12 The Brigham And Women's Hospital, Inc. Neuroprotective molecules and methods of treating neurological disorders and inducing stress granules
WO2012016184A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
EP2611420B1 (en) 2010-08-31 2019-03-27 GlaxoSmithKline Biologicals SA Lipids suitable for liposomal delivery of protein-coding rna
KR101878361B1 (ko) 2010-09-20 2018-08-20 시르나 쎄러퓨틱스 인코퍼레이티드 올리고뉴클레오티드 전달을 위한 신규 저분자량 양이온성 지질
EP2621480B1 (en) 2010-09-30 2018-08-15 Sirna Therapeutics, Inc. Low molecular weight cationic lipids for oligonucleotide delivery
CA2813024A1 (en) 2010-10-21 2012-04-26 Merck Sharp & Dohme Corp. Novel low molecular weight cationic lipids for oligonucleotide delivery
US9617461B2 (en) 2010-12-06 2017-04-11 Schlumberger Technology Corporation Compositions and methods for well completions
EP2663548B1 (en) 2011-01-11 2017-04-05 Alnylam Pharmaceuticals, Inc. Pegylated lipids and their use for drug delivery
WO2012162210A1 (en) 2011-05-26 2012-11-29 Merck Sharp & Dohme Corp. Ring constrained cationic lipids for oligonucleotide delivery
WO2013016058A1 (en) 2011-07-22 2013-01-31 Merck Sharp & Dohme Corp. Novel bis-nitrogen containing cationic lipids for oligonucleotide delivery
EP3456317A1 (en) 2011-09-27 2019-03-20 Alnylam Pharmaceuticals, Inc. Di-aliphatic substituted pegylated lipids
EA032088B1 (ru) 2011-10-27 2019-04-30 Массачусетс Инститьют Оф Текнолоджи Аминокислотные производные, функционализованные на n-конце, способные образовывать микросферы, инкапсулирующие лекарственное средство
WO2013070324A1 (en) 2011-11-07 2013-05-16 University Of Louisville Research Foundation, Inc. Edible plant-derived microvesicle compositions for diagnosis and treatment of disease
EP2781507B1 (en) 2011-11-18 2017-03-22 Nof Corporation Cationic lipid having improved intracellular kinetics
US20140308304A1 (en) 2011-12-07 2014-10-16 Alnylam Pharmaceuticals, Inc. Lipids for the delivery of active agents
JP6305344B2 (ja) 2011-12-07 2018-04-04 アルニラム・ファーマシューティカルズ・インコーポレーテッド 活性作用物質の送達のための生分解性脂質
US9463247B2 (en) 2011-12-07 2016-10-11 Alnylam Pharmaceuticals, Inc. Branched alkyl and cycloalkyl terminated biodegradable lipids for the delivery of active agents
TWI594767B (zh) 2011-12-12 2017-08-11 協和醱酵麒麟有限公司 含有陽離子性脂質之藥物傳遞系統用脂質奈米粒子
WO2013116126A1 (en) 2012-02-01 2013-08-08 Merck Sharp & Dohme Corp. Novel low molecular weight, biodegradable cationic lipids for oligonucleotide delivery
ES2898912T3 (es) 2012-02-24 2022-03-09 Arbutus Biopharma Corp Lípidos catiónicos de trialquilo y métodos para su uso
AU2013240051B2 (en) 2012-03-27 2017-11-30 Sirna Therapeutics, Inc. Diether based biodegradable cationic lipids for siRNA delivery
EA030650B1 (ru) 2013-03-08 2018-09-28 Новартис Аг Липиды и липидные композиции для доставки активных агентов
JP6620093B2 (ja) 2013-07-23 2019-12-11 アービュートゥス バイオファーマ コーポレイションＡｒｂｕｔｕｓ Ｂｉｏｐｈａｒｍａ Ｃｏｒｐｏｒａｔｉｏｎ メッセンジャーｒｎａを送達するための組成物及び方法
KR102096796B1 (ko) 2013-10-22 2020-05-27 샤이어 휴먼 지네틱 테라피즈 인크. 메신저 rna의 전달을 위한 지질 제형
US9365610B2 (en) 2013-11-18 2016-06-14 Arcturus Therapeutics, Inc. Asymmetric ionizable cationic lipid for RNA delivery
WO2015073587A2 (en) 2013-11-18 2015-05-21 Rubius Therapeutics, Inc. Synthetic membrane-receiver complexes
CN105873902B (zh) 2013-11-18 2019-03-08 阿克丘勒斯治疗公司 用于rna递送的可电离的阳离子脂质
PT3083556T (pt) 2013-12-19 2020-03-05 Novartis Ag Lípidos e composições lipídicas para a entrega de agentes ativos
EP4019506A1 (en) 2013-12-19 2022-06-29 Novartis AG Lipids and lipid compositions for the delivery of active agents
EP3125927B1 (en) 2014-04-01 2021-01-27 Rubius Therapeutics, Inc. Methods and compositions for immunomodulation
PT3766916T (pt) 2014-06-25 2022-11-28 Acuitas Therapeutics Inc Novos lípidos e formulações de nanopartículas lipídicas para distribuição de ácidos nucleicos
WO2016115632A1 (en) * 2015-01-21 2016-07-28 Exerkine Corporation Method for treating mitochondrial disease
US20180135012A1 (en) 2015-05-13 2018-05-17 Rubius Therapeutics, Inc. Membrane-receiver complex therapeutics
HRP20230494T1 (hr) 2015-06-19 2023-08-04 Massachusetts Institute Of Technology Alkenil supstituirani 2,5-piperazindioni i njihova upotreba u pripravcima za isporuku sredstva subjektu ili stanici
EP3313829B1 (en) 2015-06-29 2024-04-10 Acuitas Therapeutics Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
US20180362974A1 (en) 2015-07-02 2018-12-20 University Of Louisville Research Foundation, Inc. EDIBLE PLANT-DERIVED MICROVESICLE COMPOSITIONS FOR DELIVERY OF miRNA AND METHODS FOR TREATMENT OF CANCER
PT3350157T (pt) 2015-09-17 2022-03-18 Modernatx Inc Compostos e composições para administração intracelular de agentes terapêuticos
FI3368507T3 (fi) 2015-10-28 2023-03-21 Acuitas Therapeutics Inc Uusia lipidejä ja lipidinanopartikkeliformulaatioita nukleiinihappojen annostelemiseksi
PL3386484T3 (pl) 2015-12-10 2022-07-25 Modernatx, Inc. Kompozycje i sposoby dostarczania środków terapeutycznych
EP3397613A1 (en) 2015-12-30 2018-11-07 Acuitas Therapeutics Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
SG11201805253SA (en) 2016-01-11 2018-07-30 Rubius Therapeutics Inc Compositions and methods related to multimodal therapeutic cell systems for cancer indications
EP3436077A1 (en) 2016-03-30 2019-02-06 Intellia Therapeutics, Inc. Lipid nanoparticle formulations for crispr/cas components
JP7080826B2 (ja) 2016-05-16 2022-06-06 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム カチオン性スルホンアミドアミノ脂質および両親媒性両性イオンアミノ脂質
US20200315967A1 (en) 2016-06-24 2020-10-08 Modernatx, Inc. Lipid nanoparticles
EP3481943A1 (en) 2016-07-07 2019-05-15 Rubius Therapeutics, Inc. Compositions and methods related to therapeutic cell systems expressing exogenous rna
EP3532103A1 (en) 2016-10-26 2019-09-04 Acuitas Therapeutics, Inc. Lipid nanoparticle formulations
CA3045331A1 (en) 2016-12-02 2018-06-07 Rubius Therapeutics, Inc. Compositions and methods related to cell systems for penetrating solid tumors
KR20190117667A (ko) 2017-02-17 2019-10-16 루비우스 테라퓨틱스, 아이엔씨. 기능화된 적혈구 세포
EP3622079A1 (en) 2017-05-08 2020-03-18 Flagship Pioneering Innovations V, Inc. Compositions for facilitating membrane fusion and uses thereof
WO2019051289A1 (en) 2017-09-08 2019-03-14 Generation Bio Co. FORMULATIONS OF LIPID NANOPARTICLES OF NON-VIRAL CAPSID-FREE DNA VECTORS
AU2018339089A1 (en) 2017-09-29 2020-04-09 Intellia Therapeutics, Inc. Polynucleotides, compositions, and methods for genome editing
WO2019067992A1 (en) 2017-09-29 2019-04-04 Intellia Therapeutics, Inc. Formulations
CN112601816B (zh) 2018-05-11 2024-12-17 比姆医疗股份有限公司 使用可编程碱基编辑器系统遏止病原性突变的方法
CA3113651A1 (en) 2018-09-20 2020-03-26 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
MX2021003567A (es) * 2018-09-26 2021-08-24 Univ Case Western Reserve Métodos y composiciones para aumentar la expresión de proteínas y/o tratar un trastorno por haploinsuficiencia.
AU2019361129A1 (en) 2018-10-18 2021-05-20 Acuitas Therapeutics, Inc. Lipids for lipid nanoparticle delivery of active agents
MX2021005969A (es) 2018-11-21 2021-09-14 Translate Bio Inc Tratamiento de la fibrosis quística mediante el suministro de arnm que codifica cftr nebulizado.
US11166996B2 (en) 2018-12-12 2021-11-09 Flagship Pioneering Innovations V, Inc. Anellovirus compositions and methods of use
KR20210151049A (ko) * 2019-01-18 2021-12-13 플래그쉽 파이어니어링, 인크. Trem 조성물 및 이의 용도
WO2020219876A1 (en) 2019-04-25 2020-10-29 Intellia Therapeutics, Inc. Ionizable amine lipids and lipid nanoparticles
US20220228147A1 (en) * 2019-05-31 2022-07-21 Flagship Pioneering, Inc. Uses of trem compositions to modulate trna pools
US20220364092A1 (en) * 2019-11-04 2022-11-17 Flagship Pioneering, Inc. Trem compositions for con-rare codons and related uses

Also Published As

Publication number Publication date
IL298539A (en) 2023-01-01
CN116018405A (zh) 2023-04-25
KR20230029685A (ko) 2023-03-03
WO2021243290A1 (en) 2021-12-02
AU2021278984A1 (en) 2022-11-17
US20230203510A1 (en) 2023-06-29
CA3180101A1 (en) 2021-12-02
EP4158031A1 (en) 2023-04-05
JP2023527413A (ja) 2023-06-28

Similar Documents

Publication Publication Date Title
MX2022015042A (es) Composiciones de trem y métodos relacionados con las mismas.
WO2018004308A3 (ko) 신규 내열성 과당-6-인산-3-에피머화 효소 및 이를 이용한 알룰로스 제조방법
MX2023001394A (es) Genes del factor viii optimizados.
WO2023049742A3 (en) Engineered casx repressor systems
MX2022012189A (es) Composiciones que comprenden una variante del polipéptido cas12i2 y usos de las mismas.
WO2021257730A3 (en) Cells modified by a cas12i polypeptide
MY191029A (en) Novel polypeptide and method of producing imp using the same
MX2021005254A (es) Produccion recombinante de una preparacion de peptido de colageno y uso de la misma.
CA3010631A1 (en) Processes for the preparation of 2,5-furandicarboxylic acid and intermediates and derivatives thereof
WO2004033659A3 (en) Novel tumor suppressor gene and compositions and methods for making and using the same
MX2019000082A (es) Una novedosa tagatosa-6-fosfato fosfatasa termoestable y un procedimiento para producir tagatosa usando la misma.
WO2007144190A3 (en) Plants with modulated expression of nac transcription factors having enhanced yield-related traits and a method for making the same
WO2020223514A3 (en) Novel omni-50 crispr nuclease
WO2023073190A8 (en) Rna constructs and uses thereof
AU2008220715A8 (en) Plants having enhanced yield-related traits and a method for making the same
SI1670779T1 (sl) Postopki za pripravo 3-metilamino-1-(tien-2-il)-propan ola
MX2023012605A (es) Acidos nucleicos modificados con glicano, metodos de preparacion y usos terapeuticos.
MX2022005644A (es) Vectores vegetales, composiciones y usos relacionados con los mismos.
WO2023034959A3 (en) Polypeptides and methods for modifying nucleic acids
PH12023552771A1 (en) Compositions comprising a variant polypeptide and uses thereof
WO2021231808A3 (en) Compositions and methods for treating gjb2-associated hearing loss
WO2020074977A9 (en) An improved process for the preparation of recombinant lectin protein
WO2019229064A3 (en) Method for producing albicanol compounds
WO2023039534A3 (en) Compositions comprising a cas12i polypeptide and uses thereof
EP4282960A3 (en) Modified lipase and use thereof